Adagene Announces Completion Of Patient Enrollment In Its Phase 2 Study Of Muzastotug To Treat Microsatellite Stable Colorectal Cancer Without Liver Metastases
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
Adagene Doses First Patient In Phase 1 Study Evaluating Combination Of Muzastotug And INCA33890, Incyte’s TGFβR2 × PD-1 Bispecific Antibody, In Patients With Microsatellite Stable Colorectal Cancer
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $7 Price Target
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
China’s NMPA Approves Adagene’s IND Application For ADG138, Double-Masked HER2×CD3 Bispecific T Cell Engager Built On Proprietary SAFEbody Precision Masking Technology
Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Third Arc Bio Selects First Lead Candidate Upon 2025 Amended Strategic License Deal With Adagene
Chardan Capital Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
Adagene to Participate in Three Upcoming Investor Conferences
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Adagene H1 Adj. EPS $(0.20) Misses $(0.10) Estimate, Sales $1.620M
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.